Decoding CNS Drug Discovery with SynFire® iP
Our Unique Approach
NeuCyte is a biotech company focused on generating quality iPSC-derived neural cells to develop treatments for neurological disorders. Our vision and approach span many biopharmaceutical sectors as our SynFire technology is utilized to find treatments and solutions for AD, ALS/FTD, rare disorders, epilepsy, autism and other neurodegenerative diseases.
®
About Us
SynFire Technology
Based on the advantageous SynFire technology for generating human induced pluripotent stem cell (iPSC)-derived induced neuronal cells (iNs), NeuCyte has developed a proprietary in vitro human neural platform for complex electrophysiological and morphological readouts suited for target identification and validation, efficacy testing and neurotoxicity assessment.
Using patient-derived and genetically engineered defined neural cell types, NeuCyte builds unique cell-based assays for modeling neurological and neurodegenerative disorders.
Learn More
Drug Discovery
With our proprietary technology platform and exciting collaborations, NeuCyte is actively pursuing drug discovery programs for several genetically defined neurological diseases.
Learn More
Latest News
Society for Neuroscience
Chicago
October 5-9, 2024.
Meet us at SfN24 and see how NeuCyte is decoding CNS disease with our customized iPSC-derived cell products.
Mountain View, CA, USA, August 14, 2023. NeuCyte, Inc., an innovative biotechnology company focused on developing novel treatments for neurological and neurodegenerative disorders, announced that the company has been awarded a National Institute of Health Small Business Technology Transfer (STTR) grant in collaboration with University of California at San Francisco (UCSF) and Acoustic Bio to develop a microfluidics-based high-throughput drug-screening platform for Alzheimer Disease/Alzheimer Disease-related Dementias (AD/ADRD).
Looking for an exciting and rewarding career opportunity?
©2025 NeuCyte, Inc